ArticleLiver cancer2024

Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study.

Richard S Finn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.